These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 33524928)
1. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. Gómez-Moreno M; Sánchez-Seco VG; Moreno-García S; Cámara PS; Sabin-Muñoz J; Ayuso-Peralta L; Oreja-Guevara C; Díaz-Díaz J; Sainz de la Maza S; Costa-Frossard L; Pilo de la Fuente B; Aladro-Benito Y Mult Scler Relat Disord; 2021 Apr; 49():102747. PubMed ID: 33524928 [TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y; J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647 [TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463 [TBL] [Abstract][Full Text] [Related]
4. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Wood CH; Robertson NP; Htet ZM; Tallantyre EC Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268 [TBL] [Abstract][Full Text] [Related]
5. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245 [TBL] [Abstract][Full Text] [Related]
6. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension. Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099 [TBL] [Abstract][Full Text] [Related]
8. [Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis]. de Sá J; Ferreira J; Macedo AM Rev Neurol; 2023 Jan; 76(s01):S1-S6. PubMed ID: 36683265 [TBL] [Abstract][Full Text] [Related]
9. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population. Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308 [TBL] [Abstract][Full Text] [Related]
10. Risk of cancer among Finnish multiple sclerosis patients. Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761 [TBL] [Abstract][Full Text] [Related]
11. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304 [TBL] [Abstract][Full Text] [Related]
12. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y; Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273 [TBL] [Abstract][Full Text] [Related]
14. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580 [TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Su W; Kansal A; Vicente C; Deniz B; Sarda S J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475 [TBL] [Abstract][Full Text] [Related]
17. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report. Ciurleo R; Sessa E; Marino S; D'Aleo G; Bramanti P; Rifici C Medicine (Baltimore); 2019 Apr; 98(17):e15185. PubMed ID: 31027063 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]